MIStar

Deeplink Medical has developed its offer around the MIRIO platform, which adjusts to the different use cases and needs of actors involved in medical imaging in oncology, in the clinic, and in routine. Our services rely on 3 different but complementary offers, MIRIO, a platform for the follow-up of solid tumors evaluations, and the therapeutic response of patients in oncology. The patient pathway allows a link between hospital facilities and liberal medicine. An Imaging CRO, for the follow-up of imaging data in oncological clinical trials. A scientific board supports the development of our solutions. Collaborative workflow platform structuring imaging data and radiological evaluations for patients with solid tumors allowing structuration of data in real-time (according to RECIST 1.1 and iRECIST) directly in investigation sites at the first creation of the data. Real-time evaluation of the therapeutic response of treatments according to international guidelines RECIST 1.1 and iRECIST.

Brainlab's Elements Contrast Clearance Analysis is an MRI-based methodology designed to differentiate regions of contrast clearance and accumulation in brain tumor datasets. This high-resolution analysis provides additional insights to support ongoing assessment and decision-making in clinical specialties such as radiosurgery, radiation oncology, neurosurgery, neuro-oncology, and neuroradiology. The process involves acquiring two standard 3D T1-weighted MRIs, one approximately 5 minutes and another 60 to 105 minutes after the injection of a standard dose of contrast agent. The first series is subtracted from the second to generate volumetric maps that distinguish regions of contrast clearance (depicted in blue) from contrast accumulation (depicted in red). These results enable clinicians to assess radiation effects versus tumor regrowth, facilitating more informed decisions for initial and follow-up treatments.